首页> 外文期刊>Expert opinion on biological therapy >Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity.
【24h】

Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity.

机译:基于整合酶缺陷的慢病毒载体的疫苗:一种诱导T细胞免疫的新载体。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: The development of new strategies for the induction of potent and broad immune responses is of high priority in the vaccine field. In this setting, integrase-defective lentiviral vectors (IDLV) represent a new and promising delivery system for immunization purposes. AREAS COVERED: In this review we describe the development and application of IDLV for vaccination. IDLV are turning out to be a new class of vectors endowed with peculiar characteristics, setting them apart from the parental integration-competent lentiviral vectors. Recent data suggest that IDLV are able to induce strong antigen-specific immune responses in terms of quantity, persistence and quality of CD8(+) T cell response following a single immunization in mice. EXPERT OPINION: IDLV are a recent acquisition in the field of genetic immunization, thus allowing for the opportunity of further upgrading, including increasing antigen expression and potency of immune response. Based on recent reports showing the potential of IDLV for immunization in mouse models, further development and validation of IDLV, including comparison with other vaccine protocols and use in non-human primate models, are warranted.
机译:引言:在疫苗领域,开发有效和广泛的免疫应答诱导新策略是非常重要的。在这种情况下,整合酶缺陷型慢病毒载体(IDLV)代表了一种新的有希望的免疫系统。涵盖的领域:在这篇综述中,我们描述了IDLV疫苗的开发和应用。事实证明,IDLV是一类具有特殊特征的新型载体,使它们与具有亲本整合能力的慢病毒载体区分开来。最近的数据表明,IDLV能够在小鼠单次免疫后就CD8(+)T细胞反应的数量,持久性和质量引起强烈的抗原特异性免疫反应。专家意见:IDLV是基因免疫领域中的最新成果,因此有机会进一步升级,包括增加抗原表达和增强免疫反应能力。根据最近的报告显示IDLV在小鼠模型中进行免疫的潜力,有必要进一步开发和验证IDLV,包括与其他疫苗方案进行比较以及在非人灵长类动物模型中使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号